We study the efficiency of galactic feedback in the early Universe by stacking the C II 158
μ
m emission in a large sample of normal star-forming galaxies at 4 <
z
< 6 from the ALMA Large Program ...to INvestigate C II at Early times (ALPINE) survey. Searching for typical signatures of outflows in the high-velocity tails of the stacked C II profile, we observe (i) deviations from a single-component Gaussian model in the combined residuals and (ii) broad emission in the stacked C II spectrum, with velocities of |
v
|≲500 km s
−1
. The significance of these features increases when stacking the subset of galaxies with star formation rates (SFRs) higher than the median (SFR
med
= 25
M
⊙
yr
−1
), thus confirming their star-formation-driven nature. The estimated mass outflow rates are comparable to the SFRs, yielding mass-loading factors of the order of unity (similarly to local star-forming galaxies), suggesting that star-formation-driven feedback may play a lesser role in quenching galaxies at
z
> 4. From the stacking analysis of the datacubes, we find that the combined C II core emission (|
v
|< 200 km s
−1
) of the higher-SFR galaxies is extended on physical sizes of ∼30 kpc (diameter scale), well beyond the analogous C II core emission of lower-SFR galaxies and the stacked far-infrared continuum. The detection of such extended metal-enriched gas, likely tracing circumgalactic gas enriched by past outflows, corroborates previous similar studies, confirming that baryon cycle and gas exchanges with the circumgalactic medium are at work in normal star-forming galaxies already at early epochs.
Aims.
We study the coevolution between the black hole accretion rate (BHAR) and the star formation rate (SFR) in different phases of galaxy life: main-sequence star-forming galaxies, quiescent ...galaxies, and starburst galaxies at different cosmic epochs.
Methods.
We exploited the unique combination of depth and area in the COSMOS field and took advantage of the X-ray data from the
Chandra
COSMOS-Legacy survey and the extensive multiwavelength ancillary data presented in the COSMOS2015 catalog, including in particular the UVista Ultra-deep observations. These large datasets allowed us to perform an X-ray stacking analysis and combine it with detected sources in a broad redshift interval (0.1 <
z
< 3.5) with unprecedented statistics for normal star-forming, quiescent, and starburst galaxies. The X-ray luminosity was used to predict the black holeAR, and a similar stacking analysis on far-infrared
Herschel
maps was used to measure the corresponding obscured SFR for statistical samples of sources in different redshifts and stellar mass bins.
Results.
We focus on the evolution of the average SFR-stellar mass (
M
*
) relation and compare it with the BHAR-
M
*
relation. This extends previous works that pointed toward the existence of almost linear correlations in both cases. We find that the ratio between BHAR and SFR does not evolve with redshift, although it depends on stellar mass. For the star-forming populations, this dependence on
M
*
has a logarithmic slope of ∼0.6 and for the starburst sample, the slope is ∼0.4. These slopes are both at odds with quiescent sources, where the dependence remains constant (log(BHAR/SFR) ∼ −3.4). By studying the specific BHAR and specific SFR, we find signs of downsizing for
M
*
and black hole mass (
M
BH
) in galaxies in all evolutionary phases. The increase in black hole mass-doubling timescale was particularly fast for quiescents, whose super-massive black holes grew at very early times, while accretion in star-forming and starburst galaxies continued until more recent times.
Conclusions.
Our results support the idea that the same physical processes feed and sustain star formation and black hole accretion in star-forming galaxies while the starburst phase plays a lesser role in driving the growth of the supermassive black holes, especially at high redshift. Our integrated estimates of the
M
*
−
M
BH
relation at all redshifts are consistent with independent determinations of the local
M
*
−
M
BH
relation for samples of active galactic nuclei. This adds key evidence that the evolution in the BHAR/SFR is weak and its normalization is relatively lower than that of local dynamical
M
*
−
M
BH
relations.
Over the past decade, several works have used the ratio between total (rest 8−1000
μ
m) infrared and radio (rest 1.4 GHz) luminosity in star-forming galaxies (
q
IR
), often referred to as the ...infrared-radio correlation (IRRC), to calibrate the radio emission as a star formation rate (SFR) indicator. Previous studies constrained the evolution of
q
IR
with redshift, finding a mild but significant decline that is yet to be understood. Here, for the first time, we calibrate
q
IR
as a function of
both
stellar mass (
M
⋆
) and redshift, starting from an
M
⋆
-selected sample of > 400 000 star-forming galaxies in the COSMOS field, identified via (
NUV
−
r
)/(
r
−
J
) colours, at redshifts of 0.1 <
z
< 4.5. Within each (
M
⋆
,
z
) bin, we stacked the deepest available infrared/sub-mm and radio images. We fit the stacked IR spectral energy distributions with typical star-forming galaxy and IR-AGN templates. We then carefully removed the radio AGN candidates via a recursive approach. We find that the IRRC evolves primarily with
M
⋆
, with more massive galaxies displaying a systematically lower
q
IR
. A secondary, weaker dependence on redshift is also observed. The best-fit analytical expression is the following:
q
IR
(
M
⋆
,
z
) = (2.646 ± 0.024) × (1 +
z
)
( − 0.023 ± 0.008)
–(0.148 ± 0.013) × (log
M
⋆
/
M
⊙
− 10). Adding the UV dust-uncorrected contribution to the IR as a proxy for the total SFR would further steepen the
q
IR
dependence on
M
⋆
. We interpret the apparent redshift decline reported in previous works as due to low-
M
⋆
galaxies being progressively under-represented at high redshift, as a consequence of binning only in redshift and using either infrared or radio-detected samples. The lower IR/radio ratios seen in more massive galaxies are well described by their higher observed SFR surface densities. Our findings highlight the fact that using radio-synchrotron emission as a proxy for SFR requires novel
M
⋆
-dependent recipes that will enable us to convert detections from future ultra-deep radio surveys into accurate SFR measurements down to low-
M
⋆
galaxies with low SFR.
Having demonstrated short-term weight loss with liraglutide in this group of obese adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for sustaining weight loss ...(secondary outcome) over 2 years.
A randomized, double-blind, placebo-controlled 20-week study with 2-year extension (sponsor unblinded at 20 weeks, participants/investigators at 1 year) in 19 European clinical research centers.
A total of 564 adults (n=90-98 per group; body mass index 30-40 kg m(-2)) enrolled, 398 entered the extension and 268 completed the 2-year trial. Participants received diet (500 kcal deficit per day) and exercise counseling during 2-week run-in, before being randomly assigned (with a telephone or web-based system) to once-daily subcutaneous liraglutide (1.2, 1.8, 2.4 or 3.0 mg, n=90-95), placebo (n=98) or open-label orlistat (120 mg × 3, n=95). After 1 year, liraglutide/placebo recipients switched to liraglutide 2.4 mg, then 3.0 mg (based on 20-week and 1-year results, respectively). The trial ran from January 2007-April 2009 and is registered with Clinicaltrials.gov, number NCT00480909.
From randomization to year 1, liraglutide 3.0 mg recipients lost 5.8 kg (95% confidence interval 3.7-8.0) more weight than those on placebo and 3.8 kg (1.6-6.0) more than those on orlistat (P0.0001; intention-to-treat, last-observation-carried-forward). At year 2, participants on liraglutide 2.4/3.0 mg for the full 2 years (pooled group, n=184) lost 3.0 kg (1.3-4.7) more weight than those on orlistat (n=95; P<0.001). Completers on liraglutide 2.4/3.0 mg (n=92) maintained a 2-year weight loss of 7.8 kg from screening. With liraglutide 3.0 mg, 20-week body fat decreased by 15.4% and lean tissue by 2.0%. The most frequent drug-related side effects were mild to moderate, transient nausea and vomiting. With liraglutide 2.4/3.0 mg, the 2-year prevalence of prediabetes and metabolic syndrome decreased by 52 and 59%, with improvements in blood pressure and lipids.
Liraglutide is well tolerated, sustains weight loss over 2 years and improves cardiovascular risk factors.
We obtained optical/near-IR rest-frame Magellan FIRE spectra (including Paβ and Paγ) of 25 starburst galaxies at 0.5 < z < 0.9, with average star formation rates (SFRs) seven times above the main ...sequence (MS). We find that Paschen-to-Balmer line ratios saturate around a constant value corresponding to AV ∼ 2-3 mag, while line-to-IR-luminosity ratios suggest a large range of more extreme obscurations and appear to be uncorrelated with the former. This behavior is not consistent with standard attenuation laws derived for local and distant galaxies, yet is remarkably consistent with observations of starburst cores in which young stars and dust are homogeneously mixed. This model implies AV = 2-30 mag attenuation to the center of starburst cores, with a median of ∼9 mag (a factor of 4000). X-ray hardness ratios for six AGNs in our sample and column densities derived from observed dust masses and radio sizes independently confirm this level of attenuation. In these conditions observed optical/near-IR emission comes from surface regions, while inner starburst cores are invisible. We thus attribute the high N ii/H ratios to widespread shocks from accretion, turbulence, and dynamic disturbances rather than to AGNs. The large range of optical depths demonstrates that substantial diversity is present within the starburst population, possibly connected to different merger phases or progenitor properties. The majority of our targets are, in fact, morphologically classified as mergers. We argue that the extreme obscuration provides in itself smoking gun evidence of their merger origin, and a powerful tool for identifying mergers at even higher redshifts.
Liraglutide 3.0 mg, with diet and exercise, produced substantial weight loss over 1 year that was sustained over 2 years in obese non-diabetic adults. Nausea was the most frequent side effect.
To ...evaluate routinely collected data on nausea and vomiting among individuals on liraglutide and their influence on tolerability and body weight.
A randomized, placebo-controlled, double-blind 20-week study with an 84-week extension (sponsor unblinded at 20 weeks, open-label after 1 year) in eight European countries (Clinicaltrials.gov: NCT00422058).
After commencing a 500-kcal/day deficit diet plus exercise, 564 participants (18-65 years, body mass index (BMI) 30-40 kg m(-2)) were randomly assigned (after a 2-week run-in period) to once-daily subcutaneous liraglutide (1.2, 1.8, 2.4 or 3.0 mg), placebo or open-label orlistat (120 mg × 3 per day). After 1 year, participants on liraglutide/placebo switched to liraglutide 2.4 mg, and subsequently, to liraglutide 3.0 mg (based on 20-week and 1-year results, respectively).
The intention-to-treat population comprised 561 participants (n=90-98 per arm, age 45.9±10.3 years, BMI 34.8±2.7 kg m(-2) (mean±s.d.)). In year 1, more participants reported ⩾1 episode of nausea/vomiting on treatment with liraglutide 1.2-3.0 mg (17-38%) than with placebo or orlistat (both 4%, P⩽0.001). Most episodes occurred during dose escalation (weeks 1-6), with 'mild' or 'moderate' symptoms. Among participants on liraglutide 3.0 mg, 48% reported some nausea and 13% some vomiting, with considerable variation between countries, but only 4 out of 93 (4%) reported withdrawals. The mean 1-year weight loss on treatment with liraglutide 3.0 mg from randomization was 9.2 kg for participants reporting nausea/vomiting episodes, versus 6.3 kg for those with none (a treatment difference of 2.9 kg (95% confidence interval 0.5-5.3); P=0.02). Both weight losses were significantly greater than the respective weight losses for participants on placebo (P<0.001) or orlistat (P<0.05). Quality-of-life scores at 20 weeks improved similarly with or without nausea/vomiting on treatment with liraglutide 3.0 mg.
Transient nausea and vomiting on treatment with liraglutide 3.0 mg was associated with greater weight loss, although symptoms appeared tolerable and did not attenuate quality-of-life improvements. Improved data collection methods on nausea are warranted.
We present a new modeling of the X-ray luminosity function (XLF) of active galactic nuclei (AGNs) out to z ∼ 3, dissecting the contributions of main-sequence (MS) and starburst (SB) galaxies. For ...each galaxy population, we convolved the observed galaxy stellar mass (M ) function with a grid of M -independent Eddington ratio (λEDD) distributions, normalized via empirical black hole accretion rate (BHAR) to star formation rate (SFR) relations. Our simple approach yields an excellent agreement with the observed XLF since z ∼ 3. We find that the redshift evolution of the observed XLF can only be reproduced through an intrinsic flattening of the λEDD distribution and with a positive shift of the break λ*, consistent with an antihierarchical behavior. The AGN accretion history is predominantly made by massive (1010 < M < 1011 M ) MS galaxies, while SB-driven BH accretion, possibly associated with galaxy mergers, becomes dominant only in bright quasars, at log(LX/erg s−1) > 44.36 + 1.28 × (1 + z). We infer that the probability of finding highly accreting (λEDD > 10%) AGNs significantly increases with redshift, from 0.4% (3.0%) at z = 0.5%-6.5% (15.3%) at z = 3 for MS (SB) galaxies, implying a longer AGN duty cycle in the early universe. Our results strongly favor a M -dependent ratio between BHAR and SFR, as BHAR/SFR ∝ , supporting a nonlinear BH buildup relative to the host. Finally, this framework opens potential questions on super-Eddington BH accretion and different λEDD prescriptions for understanding the cosmic BH mass assembly.
The gut incretin hormone glucagon-like peptide 1 (GLP-1) is released in response to ingested nutrients and enhances insulin secretion. In addition to its insulinotropic properties, GLP-1 has been ...shown to have natriuretic actions paralleled by a diminished proton secretion. We therefore studied the role of the GLP-1 receptor agonist exendin-4 in modulating the activity of Na(+)/H(+) exchanger NHE3 in LLC-PK(1) cells. We found that NHE3-mediated Na(+)-dependent intracellular pH (pH(i)) recovery decreased approximately 50% after 30-min treatment with 1 nM exendin-4. Pharmacological inhibitors and cAMP analogs that selectively activate protein kinase A (PKA) or the exchange protein directly activated by cAMP (EPAC) demonstrated that regulation of NHE3 activity by exendin-4 requires activation of both cAMP downstream effectors. This conclusion was based on the following observations: 1) the PKA antagonist H-89 completely prevented the effect of the PKA activator but only partially blocked the exendin-4-induced NHE3 inhibition; 2) the MEK1/2 inhibitor U-0126 abolished the effect of the EPAC activator but only diminished the exendin-4-induced NHE3 inhibition; 3) combination of H-89 and U-0126 fully prevented the effect of exendin-4 on NHE3; 4) no additive effect in the inhibition of NHE3 activity was observed when exendin-4, PKA, and EPAC activators were used together. Mechanistically, the inhibitory effect of exendin-4 on pH(i) recovery was associated with an increase of NHE3 phosphorylation. Conversely, this inhibition took place without changes in the surface expression of the transporter. We conclude that GLP-1 receptor agonists modulate sodium homeostasis in the kidney, most likely by affecting NHE3 activity.
ABSTRACT
PBC J2333.9−2343 is a giant radio galaxy at z = 0.047 with a bright central core associated to a blazar nucleus. If the nuclear blazar jet is a new phase of the jet activity, then the small ...orientation angle suggests a dramatic change of the jet direction. We present observations obtained between 2018 September and 2019 January (cadence larger than three days) with Effeslberg, SMARTS-1.3m, ZTF, ATLAS, Swift, and Fermi-LAT, and between 2019 April and 2019 July (daily cadence) with SMARTS-1.3 m and ATLAS. Large (>2 ×) flux increases are observed on time-scales shorter than a month, which are interpreted as flaring events. The cross correlation between the SMARTS-1.3 m monitoring in the NIR and optical shows that these data do not show significant time lag within the measured errors. A comparison of the optical variability properties between non-blazars and blazars AGN shows that PBC J2333.9−2343 has properties more comparable to the latter. The SED of the nucleus shows two peaks, that were fitted with a one-zone leptonic model. Our data and modelling show that the high energy peak is dominated by External Compton from the dusty torus with mild contribution from Inverse Compton from the jet. The derived jet angle of 3 deg is also typical of a blazar. Therefore, we confirm the presence of a blazar-like core in the centre of this giant radio galaxy, likely a Flat Spectrum Radio Quasar with peculiar properties.
The availability of a rapid and accurate method for the diagnosis of Photobacterium damselae subsp. piscicida (Phdp), able to discriminate its strictly correlated subsp. damselae (Phdd), formally ...known as Vibrio damsela, is essential for managing fish pasteurellosis outbreaks in farmed fish. A single‐step, high‐sensitivity real‐time PCR assay for simultaneous detection and quantification of P. damselae was designed targeting partial of the sequence of the bamB gene and tested for specificity and sensitivity on laboratory‐generated samples as well as on experimentally infected seabream tissue samples. With a limit of detection (LOD) of one copy in pure bacterial DNA, the sensitivity was higher than all methods previously reported. Validation in target and non‐target bacterial species proved the assay was able to discriminate Phdd‐Phdp subspecies from diverse hosts/geographical origins and between non‐target species. In addition, two SNPs in the target amplicon region determine two distinctive qPCR dissociation curves distinguishing between Phdp‐Phdd. This is the first time that a molecular method for P. damselae diagnosis combines detection, quantification and subspecies identification in one step. The assay holds the potential to improve the knowledge of infection dynamics and the development of better strategies to control an important fish disease.
![The ALPINE-ALMA [C II] surv...](http://api.summon.serialssolutions.com/2.0.0/image/issn/XR4PS5YY4K/0004-6361/small "The ALPINE-ALMA [C II] survey: Star-formation-driven outflows and circumgalactic enrichment in the early Universe")
PDF
